Other news
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
First Patient Dosed with TLX250-CDx in Italy for ccRCC
The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...
![RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013](https://radboudtranslationalmedicine.nl/cdn/42251bd5-d9e6-4107-bbd7-ac13f0c8609a/-/smart_resize/250x170/-/format/auto/-/quality/smart/citryll-cityview-combined-logo.png){kind=logo}
RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013
Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...
Production of novel diagnostic radionuclides in small medical cyclotrons
Employees from RTM and Radboudumc have published a new article: 'Production of novel diagnostic radi...
Interested in a collaboration?
Contact us to discuss the possibilities.